Odense University Hospital Afdeling for medicinske mave-tarmsygdomme S
Welcome,         Profile    Billing    Logout  
 2 Trials 
2 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Krag, Aleksander
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
SIPHON, NCT03308916: Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

Recruiting
N/A
6500
Europe
transient elastography, FibroScan, TE, Enhanced liver fibrosis test, ELF, Indirect serum markers of liver fibrosis, Forns index, FIB-4, APRI, AST-ALT ratio, Age-platelet ratio, Direct serum markers of liver fibrosis, Neoepitopes, Collagen products, Extracellular matrix, LiverTRAIL, Cytokeratin 18, CK18, M30, M65, Omics markers, Multi-omics markers, Lipidomics, Microbiomics, Genomics, Metagenomics, Metatranscriptomics, Transcriptomics, miRNA-omics, Metabolomics, Proteomics
Maja Thiele, Horizon 2020 - European Commission, Novo Nordisk A/S, University of Southern Denmark, Esbjerg University Hospital of South-West Jutland, Odense Municipality Alcohol Rehabilitation Unit, Svendborg Municipality Alcohol Rehabilitation Unit, University of Copenhagen, University of Oslo, Nordic Bioscience A/S, VLV Bio, Peviva AB, Manatee APS, Siemens Healthcare A/S, Steno Diabetes Center Copenhagen, Biomedical Research Foundation, Academy of Athens, European Molecular Biology Laboratory, EMBL, University of Heidelberg
Liver Diseases, Alcoholic, Fibrosis
12/25
10/35

Download Options